Cargando…

Metabolic associated fatty liver disease is a risk factor for chronic kidney disease

BACKGROUND AND AIMS: To clarify the relationship between metabolic dysfunction‐associated fatty liver disease (MAFLD) and chronic kidney disease (CKD). METHODS: The participants were divided into four groups by the presence or absence of fatty liver disease (FLD) and metabolic dysfunction (MD). MAFL...

Descripción completa

Detalles Bibliográficos
Autores principales: Hashimoto, Yoshitaka, Hamaguchi, Masahide, Okamura, Takuro, Nakanishi, Naoko, Obora, Akihiro, Kojima, Takao, Fukui, Michiaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8847128/
https://www.ncbi.nlm.nih.gov/pubmed/34561962
http://dx.doi.org/10.1111/jdi.13678
_version_ 1784651983578202112
author Hashimoto, Yoshitaka
Hamaguchi, Masahide
Okamura, Takuro
Nakanishi, Naoko
Obora, Akihiro
Kojima, Takao
Fukui, Michiaki
author_facet Hashimoto, Yoshitaka
Hamaguchi, Masahide
Okamura, Takuro
Nakanishi, Naoko
Obora, Akihiro
Kojima, Takao
Fukui, Michiaki
author_sort Hashimoto, Yoshitaka
collection PubMed
description BACKGROUND AND AIMS: To clarify the relationship between metabolic dysfunction‐associated fatty liver disease (MAFLD) and chronic kidney disease (CKD). METHODS: The participants were divided into four groups by the presence or absence of fatty liver disease (FLD) and metabolic dysfunction (MD). MAFLD was defined as having both FLD and MD, whereas CKD was defined as having an estimated glomerular filtration rate of <60 mL/min/1.73 m(2) and/or proteinuria. RESULTS: In this cross‐sectional study of 27,371 participants, the proportions of those in the non‐FLD without MD, non‐FLD with MD, FLD without MD, and MAFLD groups were 48.7, 28.2, 2.3, and 20.8%, respectively. Compared with non‐FLD without MD, MAFLD was associated with the risk of CKD (adjusted odds ratio 1.83 [1.66–2.01], P < 0.001), whereas FLD without MD was not (1.02 [0.79–1.33], P = 0.868). Moreover, compared with FLD without MD, MAFLD was associated with the risk of CKD (1.19 [1.09–1.31], P < 0.001). In this retrospective cohort study, 16,938 of 27,371 participants underwent a median 4.6 (2.0–8.1) years follow‐up, and incident data of non‐FLD without MD, non‐FLD with MD, FLD without MD, and MAFLD were 21.0, 31.1, 26.1, and 31.1 cases per 1,000 person‐years, respectively. Compared with the non‐FLD without MD, MAFLD was associated with the risk of incident CKD (adjusted hazard ratio 1.24 [1.14–1.36], P < 0.001), whereas FLD without MD was not (1.11 [0.85–1.41], P = 0.433). CONCLUSIONS: MAFLD was associated with a risk of CKD, whereas FLD without MD was not a risk for CKD.
format Online
Article
Text
id pubmed-8847128
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-88471282022-02-25 Metabolic associated fatty liver disease is a risk factor for chronic kidney disease Hashimoto, Yoshitaka Hamaguchi, Masahide Okamura, Takuro Nakanishi, Naoko Obora, Akihiro Kojima, Takao Fukui, Michiaki J Diabetes Investig Original Articles BACKGROUND AND AIMS: To clarify the relationship between metabolic dysfunction‐associated fatty liver disease (MAFLD) and chronic kidney disease (CKD). METHODS: The participants were divided into four groups by the presence or absence of fatty liver disease (FLD) and metabolic dysfunction (MD). MAFLD was defined as having both FLD and MD, whereas CKD was defined as having an estimated glomerular filtration rate of <60 mL/min/1.73 m(2) and/or proteinuria. RESULTS: In this cross‐sectional study of 27,371 participants, the proportions of those in the non‐FLD without MD, non‐FLD with MD, FLD without MD, and MAFLD groups were 48.7, 28.2, 2.3, and 20.8%, respectively. Compared with non‐FLD without MD, MAFLD was associated with the risk of CKD (adjusted odds ratio 1.83 [1.66–2.01], P < 0.001), whereas FLD without MD was not (1.02 [0.79–1.33], P = 0.868). Moreover, compared with FLD without MD, MAFLD was associated with the risk of CKD (1.19 [1.09–1.31], P < 0.001). In this retrospective cohort study, 16,938 of 27,371 participants underwent a median 4.6 (2.0–8.1) years follow‐up, and incident data of non‐FLD without MD, non‐FLD with MD, FLD without MD, and MAFLD were 21.0, 31.1, 26.1, and 31.1 cases per 1,000 person‐years, respectively. Compared with the non‐FLD without MD, MAFLD was associated with the risk of incident CKD (adjusted hazard ratio 1.24 [1.14–1.36], P < 0.001), whereas FLD without MD was not (1.11 [0.85–1.41], P = 0.433). CONCLUSIONS: MAFLD was associated with a risk of CKD, whereas FLD without MD was not a risk for CKD. John Wiley and Sons Inc. 2021-10-12 2022-02 /pmc/articles/PMC8847128/ /pubmed/34561962 http://dx.doi.org/10.1111/jdi.13678 Text en © 2021 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Articles
Hashimoto, Yoshitaka
Hamaguchi, Masahide
Okamura, Takuro
Nakanishi, Naoko
Obora, Akihiro
Kojima, Takao
Fukui, Michiaki
Metabolic associated fatty liver disease is a risk factor for chronic kidney disease
title Metabolic associated fatty liver disease is a risk factor for chronic kidney disease
title_full Metabolic associated fatty liver disease is a risk factor for chronic kidney disease
title_fullStr Metabolic associated fatty liver disease is a risk factor for chronic kidney disease
title_full_unstemmed Metabolic associated fatty liver disease is a risk factor for chronic kidney disease
title_short Metabolic associated fatty liver disease is a risk factor for chronic kidney disease
title_sort metabolic associated fatty liver disease is a risk factor for chronic kidney disease
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8847128/
https://www.ncbi.nlm.nih.gov/pubmed/34561962
http://dx.doi.org/10.1111/jdi.13678
work_keys_str_mv AT hashimotoyoshitaka metabolicassociatedfattyliverdiseaseisariskfactorforchronickidneydisease
AT hamaguchimasahide metabolicassociatedfattyliverdiseaseisariskfactorforchronickidneydisease
AT okamuratakuro metabolicassociatedfattyliverdiseaseisariskfactorforchronickidneydisease
AT nakanishinaoko metabolicassociatedfattyliverdiseaseisariskfactorforchronickidneydisease
AT oboraakihiro metabolicassociatedfattyliverdiseaseisariskfactorforchronickidneydisease
AT kojimatakao metabolicassociatedfattyliverdiseaseisariskfactorforchronickidneydisease
AT fukuimichiaki metabolicassociatedfattyliverdiseaseisariskfactorforchronickidneydisease